These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
123 related items for PubMed ID: 20034399
1. Validation of a Chinese version of disease specific quality of life scale (HFS-36) for hemifacial spasm in Taiwan. Huang YC, Fan JY, Ro LS, Lyu RK, Chang HS, Chen ST, Hsu WC, Chen CM, Wu YR. Health Qual Life Outcomes; 2009 Dec 24; 7():104. PubMed ID: 20034399 [Abstract] [Full Text] [Related]
2. Botulinum toxin improves quality of life in hemifacial spasm: validation of a questionnaire (HFS-30). Tan EK, Fook-Chong S, Lum SY, Lim E. J Neurol Sci; 2004 Apr 15; 219(1-2):151-5. PubMed ID: 15050451 [Abstract] [Full Text] [Related]
6. Factors associated with quality of life in hemifacial spasm and blepharospasm during long-term treatment with botulinum toxin. Setthawatcharawanich S, Sathirapanya P, Limapichat K, Phabphal K. Qual Life Res; 2011 Nov 15; 20(9):1519-23. PubMed ID: 21431990 [Abstract] [Full Text] [Related]
7. Validation of a short disease specific quality of life scale for hemifacial spasm: correlation with SF-36. Tan EK, Fook-Chong S, Lum SY, Thumboo J. J Neurol Neurosurg Psychiatry; 2005 Dec 15; 76(12):1707-10. PubMed ID: 16291898 [Abstract] [Full Text] [Related]
9. The Five-Year Prospective Study of Quality of Life in Hemifacial Spasm Treated with Abo-Botulinum Toxin A. Kongsaengdao S, Maneeton N, Maneeton B. Toxins (Basel); 2021 Mar 16; 13(3):. PubMed ID: 33809486 [Abstract] [Full Text] [Related]
12. Quality of life in hemifacial spasm patient after treatment with botulinum toxin A; a 24-week, double-blind, randomized, cross-over comparison of Dysport and Neuronox study. Kongsengdao S, Kritalukkul S. J Med Assoc Thai; 2012 Mar 16; 95 Suppl 3():S48-54. PubMed ID: 22619887 [Abstract] [Full Text] [Related]
14. The long-term effects of microvascular decompression on social phobia and health-related quality of life in patients with hemifacial spasm: a 3-year prospective study. Kim YG, Chang WS, Jung HH, Chang JW. Acta Neurochir (Wien); 2019 Oct 16; 161(10):2035-2042. PubMed ID: 31368052 [Abstract] [Full Text] [Related]
15. Treatment outcome correlates with knowledge of disease in hemifacial spasm. Tan EK, Hameed S, Fook-Chong S, Hussein K, Lum SY, Chan LL. Clin Neurol Neurosurg; 2008 Sep 16; 110(8):813-7. PubMed ID: 18583029 [Abstract] [Full Text] [Related]
17. Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm. Cannon PS, MacKenzie KR, Cook AE, Leatherbarrow B. Clin Exp Ophthalmol; 2010 Oct 16; 38(7):688-91. PubMed ID: 20456439 [Abstract] [Full Text] [Related]
18. [Botulinum Toxin Treatment for Hemifacial Spasm:Based on the Practical Clinical Experience in the Neurology Outpatient Clinic]. Kita K. No Shinkei Geka; 2024 Jan 16; 52(1):102-111. PubMed ID: 38246676 [Abstract] [Full Text] [Related]